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Table 1. New Cases of childhood lymphomas in Poland
Childhood lymphomas constitute the third
most common group of malignancies in the
population aged from 0 to 17 years [1]. It
accounts for approximately 14% of all newly
diagnosed childhood cancers. Among all
pediatric lymphomas, 60% of children are
diagnosed as having non-Hodgkin's lymphoma
(NHL), and 40% Hodgkin's disease (HD).
However, pediatric NHLs account for only
about 3% of all NHLs in Western countries. In
Poland, more than 150 new cases of childhood
lymphomas are registered each year (table 1).
In contrast to other European countries in
Poland, an almost equal distribution of NHL
and HD is has been observed in recent 5 years
[2].
The histological spectrum of childhood NHL
is considerably narrower than that of adult
NHL. The most common type in adults is the
low grade, relatively indolent NHL such as
follicular lymphoma, this histology beeng
exceedingly rare in children. Pediatric
malignant lymphomas are generally diffuse
aggressive with a propensity for widespread
dissemination. Half of them are formed with
small noncleaved cells (Burkitt's or Burkitt's
like), 30% are lymphoblastic and 20% are large
cell anaplastic lymphomas (LCAL) - [1].
In recent years, a marked improvement in
event-free survival (EFS) rates has been
achieved due to intensification of conventional
chemotherapy and efficient supportive care. In
most reports, the EFS for nonB-NHL stage 1/11
ranges from 80% to 100%, and stage III/IV
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from 65% to 80%. For B-NH these values are
90%-100% and 75%-85%, respectively. The
EFS for LCAL are lower: 50-70%. In Poland,
these rates are still not as high as in other
developed countries. The reason is that more
pediatric patients are diagnosed at advanced
stages of disease, i.e. at stage III and IV, and
only few at stage I and II. For example, 89% of
patients with childhood NB-NHL and 83% with
B-NHL are diagnosed at stage 1I1+IV [3]. Since
in these patients conventional chemotherapy is
not as efficient as in those at stage 1+11, they
can benefit from megachemotherapy, followed
by autologous hematopoietic stem cell
transplantation.
The first description of high-dose therapy
and autologous bone marrow transplantation
were recorded as early as 1957 for patients
with non-Hodgkin's lymphoma [4]. However,
the authors were not able to show any
evidence of curative potential of the method
and this approach was not widely endorsed at
that time. In 1978, a clinical study of
Appelbaum and others [5] suggested for the
first time that patients with refractory
lymphoma could sometimes experience a long-
term relapse-free survival after high-dose
chemotherapy, followed by bone marrow
transplantation. These results caused a
renewed interest in HDT + BMT, generating
studies designed to determine which
lymphoma patients were the best candidates
for the procedure. Until 1994, the gold
standard for autograft was bone marrow. After
1994, the Autologous Blood and Marrow
Transplant Registry for North America
(ABMTR), the International Bone Marrow
Transplant Registry (IBMTR) and the
European Group for Blood and Marrow
Transplantation (EBMT) reported that more
autologous peripheral blood stem cell
transplantations than autologous bone marrow
transplantations were performed in patients
with lymphoma (figure 1 and 2). High-dose
chemotherapy followed by hematopietic stem
cell transplantation, both autologous and
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allogeneic, becomes an accepted treatment for
NHL patients who failed or relapsed after
conventional therapies. At the same time, the
autologous blood was used with increased
frequency as a source of haematopoietic
rescue following high-dose chemotherapy. By
February,1998, a total of more than 10.000
autologous transplants were registered in NHL,
and almost 5000 in HO, with much fewer
allogeneic transplantations [6] (table 2 and 3).
It should be stressed however, that most
studies were based in adult patients, and only
4% of transplants were performed in children
below 17 years of age. The majority of patients
with NHL were transplanted while at first
complete remission, partial remission or at
second remission. Hodgkin's disease patients
were transplanted at a time of a sensitive
relapse or after second remission (table 4).
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Fig. 1. NHl: Type of transplant (lymphoma Working Party, EBMT 1998)
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Fig. 2. HD: Type of transplant (lymphoma Working Party, EBMT 1998)
Table 2. EBMT Registrations by February, 1998.
Disease
Transplant type
Auto Allo Cord blood
Ac. leukemia 9020 13214 63
CMl 1007 7039 13
ell 163 165 -
NHl 10155 1108 4
Hodgkin's 4808 163 -
M. Myeloma 4785 765 -
Solid tumours 9945 125 8
MDS/MPS 137 1423 8
SAA 4 2613 21
Imm. deficiencies 2 496 2
Inborn errors 1 1532 17
TOTAL 40027 28643 136
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Table 3. Transplants in pts with NHL and HD performed in Europe in 1998
(Gratwohl A., Baldomero H. for EBMT, 1999)
DONOR SOURCE I
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Table 4. Demographic data (Lyphoma Working Party, EBMT 1998).
Status at transplant HD(%) NHL(%)
CR1 312 (7.8) 2493 (28.2)
CR2 714 (17.9) 1598 (18.1)
~CR3 260 (6.5) 299 (3.4)
(VG) PR 705 (17.6) 2057 (23.2)
sensitive relapse 801 (20.0) 1191 (13.5)
untested relapse 346 (8.7) 250 (2.8)
resistant relapse 427 (10.7) 437 (4.9)
primary refractory 431 (10.8) 524 (5.9)
TOTAL 3996 8849
High-dose therapy followed by
haematopoietic stem cell transplantation
produces better results when compared with
conventional chemotherapy. Early non-
randomized trials showed that the probability
of a long-term disease-free survival was 20 -
50% in patients with relapsed aggressive NHL
compariel with 5 - 10% in similar patients
receiving conventional salvage therapy [7,8,9,
10, 11]. A multicentre randomized trial
conducted by Philip and co-workers [12]
included patients with chemotherapy-sensitive,
relapsed, intermediate/high-grade NHL after 2
cycles of DHAP. The patients were
randomized to receive either additional 4
cycles of DHAP or high-dose therapy followed
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by autologous BMT. Event-free survival at 5
years for the transplant arm was 46% vs. 12%
in patients receiving salvage therapy. Overall
survival rates showed also differences of 53%
vs. 32%, respectively. The data collected by
the Lymphoma Working Party indicate similar
rates for transplanted patients (figure 3 and 4).
The efficacy of high-dose therapy + HSCT in
patients with either primary refractory or
relapsed lymphoma that is chemotherapy
resistant still remains controversial. ABMTR
analysis evaluated 221 patients who had never
achieved CR prior to undergoing high dose
chemotherapy and autologous transplantation
[13]. The progression-free survival at 3 years
was 32%, and overall survival was 40%, but for
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Fig. 3. Hodgkin's disease (Lymphoma Working Party, EBMT
1998).
Fig. 4. Intermediate and high grade lymphoma (Lymphoma
Working Party, EBMT 1998)
those with resistant disease the overall survival
was 19% vs.48% for patients with sensitive
disease. The only prognostic variable found to
be significant in this study was sensitivity to
prior chemotherapy. For chemoresistant
patients with EFS of 10 - 20%, what can be
probably most beneficial is early identification
and use of modulating agents or anti-lymphoma
antibodies such as IDEC C2B8 or B1.
prognostic factors. Several studies have
reported on series of partial responders and
non-responders mixed together. Finally, front-
line treatment of aggressive NHl has varied
from study to study. Comparison of all these
results is difficult and, sometimes, even
impossible, which results in several
controversies.
The major areas of controversy are:
1. Selection of high-risk patients for
transplantation in the first remission,
2. An optimal source of stem cells,
3. Optimization of mobilization procedures,
4. An optimal transplant regimen,
5. The value of purging or positive selection,
6. Pre- or post-transplant immunotherapy
Transplantation of haemopoietic stem cells is
recommended for relapsed, chemosensitive
patients with aggressive forms of NHL. Also,
approximately 10 - 15% of patients with
chemotherapy-resistant, relapsed aggressive
NHl can benefit from this strategy [14]. The
third group which can benefit from HSCT in 40
-70% of cases are patients with residual
lymphoma following standard treatment [15,
16,17].
The currently adopted recommendations for
HSCT in childhood NHl and HD are as
follows:
• High risk NB-NHl, T-NHl, lCAl - in
CR1,
• NB-NHl regardless risk factors - in CR2,
early relapse or partial remission,
• B-NHl, T-NHl - at relapse,
• Hodgkin's disease - at relapse or in
CR2
The discussion on the optimal source of stem
has revealed the superiority of mobilized
peripheral blood progenitors over bone marrow
with respect to engraftment rates of
neutrophiles and platelets. Most advantages of
PBSCT lie in faster engraftment, lower costs
and shorter hospitalization and no evidence of
inferiority with respect to outcome.
Prospective randomized trials comparing
HlA-matched related vs. autologous
haematopoietic stem cell sources have not yet
been published. Several nonrandomized
studies have shown that alloBMT reduces the
risk of lymphomatous relapse lown to 18 -
24% vs. 38 - 69% with autoBMT. However, the
lower relapse risk has been offset by higher
transplant related mortality and serious
morbidity, thus no overall statistically
significant benefit in EFS or overall survival
could be proved. Except in unusual
circumstances, an unrelated allogeneic or
partially matched related source of stem cell
for children with lymphoma is not
recommended.
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Polish BMT centers have transplanted 26
children with NHl (December 1999).
AutoHSCT was performed in 14 children with
B-NHl, 6 lCAl and 6 with T-NHL. The
majority of patients were transplanted during
1999, and the observation time after
transplants is too short, for us to came to any
definitive conclusions as to the results of this
therapy.
Many factors lane influenced the
interpretation of the results. The patients'
populations in and between published studies
are laterogenous. Almost all studies are have
been related to adults including patients with
varying proportions of different histologies and
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The optimum mobilizing strategy should
assure that apheresis product contains:
• A maximum number of stem/progenitor
cells,
• A minimum number ofautologous tumor
cells,
• A maximum number of cytotoxic cells,
• A sufficient number of cells necessary
for recovery of immune function
following transplantation.
Currently, myelosuppressive chemotherapy
followed by haematopoietic growth factors is
used clinically to mobilize progenitor cells into
circulation for more efficient collection and to
provide rapid haematopoietic recovery after
transplant [18, 19]. The benefits of growth
factor plus chemotherapy for mobilization
include vigorous mobilization and, in some
instances, the ability to use a cycle of already
scheduled chemotherapy along with growth
factor. Not all patients exhibit haematopoietic
progenitor cell mobilization after administration
of myelosuppressive chemotherapy and
growth factors: in some patients poor or no
response can be observed. Donor
characteristics that have been associated with
poor or no response to mobilization therapies
include prior treatment with several cycles of
chemotherapy or radiation therapy and the
presence of marrow metastases [20, 21].On
the other hand, to avoid some occult tumour
cells in autograft product the mobilization
procedure should not be started before the
induction phase of the front-line therapy is
finished.
Table 5. BEAM Proctol
-7 - 6 - 5 -4 - 3 -2 0
BCND X
300mg/m
VP16 X X X X
200mg/m
Ara-C XX XX XX XX
200mg/m 112
hrs
Me1fa1an X
(A1keran)
140mg/m
X
ABMT/PBSC
T
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The optimal conditioning regimen for
transplantation in NHL is unknown and no
randomized trials have been performed. The
most commonly employed regimes are the
TBI-containing (CYITBI, VP-16/CYITBI), and
the chemotherapy only regimens (CBV, BEAM,
BEAC). In children, the most useful regime
seems to be BEAM (tab.5). An interesting
approach to conditioning regimens for
lymphoma recently been presented in
substitution of targeted radiotherapy by using
radiolabeled antibodies to replace TBI [22].
The early phase II trial evaluated 19 patients
treated with 1311-anti-CD20(B1) followed by
haematopoietic stem cell infusion. As a result,
50% of patients achieved complete remission.
Ongoing studies combine radioimmunotherapy
with other standard transplant regimens such
as BEAC.
The purging of bone marrow and the
apheresis product, or positive selection of
CD34 positive progenitor cells in some HSCT
protocols is performed in some transplantation
protocols. Significance of the tumour cell
contamination in bone marrow or apheresis
product is unclear. Only a small number of
tumour cells are clonogenic, and the host
immune system may be able to eradicate at
least some of the contaminating cells. There is
also evidence that almost all relapses occur at
sites of prior disease indicating that the relapse
is most likely due to failure of the conditioning
regimen to eradicate the bulk disease rather
than haematogenous spread of infused
clonogenic lymphoma cells. However, in the
clinical trial conducted at Dana Farber Cancer
Center, patients with low-grade NHL were
serially monitored for expression of the t(14;18)
before and after marrow purging with anti-
CD20 antibodies and complement [23].
pisease free survival of patients succesfully
purged to t(14;18) negativity was 90%
compared with DFS of 25% for patients in
which translocation was detected in the
transplanted marrow.
The feasibility of the use of positive selection
techniques for CD34+ cells has been
documented. Unfortunately, large or
randomized trials in lymphoma have not been
performed to document the effects on
engraftment, relapse rates, EFS, OS and
immunologic reconstitution.
New possibilities in the treatment of NHL
have arisen with increased knowledge of the
biology of lymphoma cells. The most promising
is immunotherapy by post-transplant
administration of interleukine 2, alfa interferon,
anti-CD19 immunotoxin, tumour reactive T-
lymphocytes to eradicate minimal residual
disease after transplantation. Addition of anti-
61
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CD20 antibodies, both unmodified and
radiolabeled, to the transplant regiment may
also improve treatment results. Vaccination of
patients with tumour specific idiotype vaccines
or mini-allogeneic transplants are worthy of
interest in future trials.
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